Colin D. White, PhD

Technology Specialist | Biotechnology

Education

BSc (Hons), Physiology, University of Aberdeen
PhD, Molecular and Cellular Biology, The University of Edinburgh

Key Technologies

Medical Devices
Biologics
Combination Products
Biomaterials
Chemistry and Manufacturing Controls
Surgical Instrumentation and Procedures

Practice Groups

Biotechnology

Admitted to Practice

Not yet admitted to practice

Location

Boston

Overview

Colin White assists the firm in biotechnology patent prosecution, utilizing his extensive experience in the areas of molecular and cellular biology, medical devices, regenerative medicine, and combination product development. He has experience drafting and successfully prosecuting utility patent applications for medical devices, medical device-drug combination products, and stem cell- and biomaterial-based treatments in the fields of orthopedics, dermatology, and oncology.

Having worked in the medical device and biotechnology industries for more than a decade, Colin has experience with early stage clinical development, as well as scaling production processes, preparing for registration trials, and asset commercialization. For example, he has designed, developed, and launched minimally invasive calcium-phosphate-based bone grafts (and associated surgical instrumentation) and a treatment for tendon degeneration as a result of chronic injury. Colin has also advanced drug-device and biologic-device combination products through pre-clinical development and early phase clinical trials in both the United States and multiple foreign countries, and successfully scaled manufacturing processes to enable commercial launches of several assets. Colin has had hundreds of Regulatory Agency interactions, both formally and informally, and has authored, reviewed, and submitted regulatory packages in virtually every major market in the world.

Prior to joining Wolf Greenfield, Colin had direct oversight of and responsibility for process engineering, manufacturing, and analytical development teams at Vertex Pharmaceuticals. In this role, Colin focused on development of a medical device-biologic combination product for the treatment of type 1 diabetes. His work resulted in successful preclinical development, FDA and international health authority clearances, and movement of the asset into early phase clinical trials. Prior to this role, Colin served in other leadership positions within both the medical device and biotechnology industries, as well as an Instructor of Pathology at Beth Israel Deaconess Medical Center and Harvard Medical School.

Recognition

Awardee, United States Department of Defense Breast Cancer Research Fellowship

Publications

Landeck JT, Walsh WR, Oliver RA, Wang T, Gordon MR, Ahn E, White CD. Temporal response of an injectable calcium phosphate material in a critical size defect. J Orthop Surg Res. 2021 Aug;16(1):496. doi: 10.1186/s13018-021-02651-8.
White CD, Toker A. Using phospho-motif antibodies to determine kinase substrates. Curr Protoc Mol Biol. 2013 Jan;Chapter 18:Unit 18.20. doi: 10.1002/0471142727.mb1820s101.
White CD, Erdemir HH, Sacks DB. IQGAP1 and its binding proteins control diverse biological functions. Cell Signal. 2012 Apr;24(4):826-34. doi:10.1016/j.cellsig.2011.12.005.
Kim H, White CD, Li Z, Sacks DB. Salmonella enterica serotype Typhimurium usurps the scaffold protein IQGAP1 to manipulate Rac1 and MAPK signalling. Biochem J. 2011 Dec;440(3):309-18. doi: 10.1042/BJ20110419.
White CD, Li Z, Dillon DA, Sacks DB. IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance. J Biol Chem. 2011 Aug;286(34):29734-47. doi: 10.1074/jbc.M111.220939.
White CD, Li Z, Sacks DB. Calmodulin binds HER2 and modulates HER2 signaling. Biochim Biophys Acta. 2011 May;1813(5):1074-82. doi: 10.1016/j.bbamcr.2010.12.016.
McNulty DE, Li Z, White CD, Sacks DB, Annan RS. MAPK scaffold IQGAP1 binds the EGF receptor and modulates its activation. J Biol Chem. 2011 Apr;286(17):15010-21. doi: 10.1074/jbc.M111.227694.
Kim H, White CD, Sacks DB. IQGAP1 in microbial pathogenesis: targeting the actin cytoskeleton. FEBS Lett. 2011 Mar;585(5):723-9. doi: 10.1016/j.febslet.2011.01.041.
White CD, Khurana H, Gnatenko DV, Li Z, Odze RD, Sacks DB, Schmidt VA. IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol. 2010 Oct;10:125. doi: 10.1186/1471-230X-10-125.
White CD, Sacks DB. Regulation of MAP kinase signaling by calcium. Methods Mol Biol. 2010 Jan;661:151-65. doi: 10.1007/978-1-60761-795-2_9.
White CD, Brown MD, Sacks DB. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett. 2009 Jun;583(12):1817-24. doi: 10.1016/j.febslet.2009.05.007.
White CD, Coetsee M, Morgan K, Flanagan CA, Millar RP, Lu ZL. A crucial role for Gαq/11, but not Gαi/o or Gαs, in gonadotropin-releasing hormone receptor-mediated cell growth inhibition. Mol Endocrinol. 2008 Nov;22(11):2520-30. doi: 10.1210/me.2008-0122.
White CD, Stewart AJ, Lu ZL, Millar RP, Morgan K. Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy. Neuroendocrinology. 2008 Feb;88(2):67-79. doi: 10.1159/000119093.
Lu ZL, Coetsee M, White CD, Millar RP. Structural determinants for ligand-receptor conformational selection in a peptide G protein-coupled receptor. J Biol Chem. 2007 Jun;282(24):17921-9. doi: 10.1074/jbc.M610413200.

Interests

A husband, and father of two young boys, Colin enjoys spending as much time as possible with his family outside of work. He is also a keen cyclist as his schedule permits.

Colin is an avid follower of current affairs and can be regularly found scrolling through various news articles to, in his words, “see what is going on in the world”. Originally from the United Kingdom, Colin still clicks on BBC News as his go to source of information.